X4 Pharmaceuticals’ (XFOR) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note published on Thursday morning,Benzinga reports. They currently have a $1.50 target price on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a report […]
HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note published on Thursday morning,Benzinga reports. They currently have a $1.50 target price on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a report […]
